The Dr. Peter Breggin Hour – 01.16.19

My guest Kim Witczak represents consumers on the FDA committee that makes recommendations to the agency about drug approval.  Kim lost her husband to suicide while he was taking the antidepressant Zoloft.  She is a remarkable example of surmounting tragedy to make a real contribution to society.   Kim is also a fountain of information about shenanigans and trends at the FDA and its partners in the pharmaceutical industry.   She has genuine insider information.  One striking new phenomenon at the FDA is fast-tracking drugs for “treatment-resistant” depression.  In other words, after patients have been poisoned with neurotoxic drugs and made worse, the FDA will help industry come up with new and more neurotoxic drugs to further overwhelm the already injured patients.   This is apparently an agency-wide trend at the FDA, which has recently approved ECT for “treatment-resistant depression.”  Instead of “First, do no harm,” the new motto of psychiatry, the FDA and the drug companies has become “Do more harm!”  You can keep up with many of these issues by subscribing to my free Frequent Alerts on www.breggin.com.  And remember you can call into my program to make a comment or to ask a question by phoning 888 874 4888 every Wednesday live at 4 pm NY Time.